Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 8/2020

01-08-2020 | Dermatitis Herpetiformis | CURRENT CLINICAL CONTROVERSY

Celiac Disease Screening for High-Risk Groups: Are We Doing It Right?

Authors: Dennis Kumral, Sana Syed

Published in: Digestive Diseases and Sciences | Issue 8/2020

Login to get access

Abstract

Celiac disease (CD) is an immune-mediated enteropathy triggered by dietary ingestion of gluten in genetically susceptible patients. CD is often diagnosed by a “case-finding” approach of symptomatic patients. In recent times, the diagnostic paradigm has shifted to investigate patients who may be asymptomatic, but are at high risk of developing CD due to shared genetic susceptibilities. These high-risk groups include first-degree relatives of CD patients and patients with Type 1 diabetes mellitus, autoimmune thyroid disease, Down’s syndrome, and Turner syndrome. Moreover, CD is often diagnosed as the cause of iron deficiency anemia or unexplained chronic diarrhea. Although screening for CD with serological tests is not recommended for the general population, it should be considered in these special populations. In this review, we explore screening for CD among high-risk groups in light of recent research and development in the CD arena.
Literature
1.
Singh P, Arora A, Strand TA, et al. Global prevalence of celiac disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16:823–836.PubMed
2.
Dubé C, Rostom A, Sy R, et al. The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review. Gastroenterology. 2005;128:S57–S67.PubMed
3.
Catassi C, Kryszak D, Bhatti B, et al. Natural history of celiac disease autoimmunity in a USA cohort followed since 1974. Ann Med. 2010;42:530–538.PubMed
4.
Rubio-Tapia A, Kyle RA, Kaplan EL, et al. Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology. 2009;137:88–93.PubMedPubMedCentral
5.
Choung RS, Ditah IC, Nadeau AM, et al. Trends and racial/ethnic disparities in gluten-sensitive problems in the United States: findings from the National Health and Nutrition Examination Surveys from 1988 to 2012. Am J Gastroenterol. 2015;110:455–461.PubMed
6.
Hin H, Bird G, Fisher P, Mahy N, Jewell D. Coeliac disease in primary care: case finding study. Br Med J. 1999;318:164–167.
7.
Sanders DS, Patel D, Stephenson TJ, et al. A primary care cross-sectional study of undiagnosed adult coeliac disease. Eur J Gastroenterol Hepatol. 2003;15:407–413.PubMed
8.
West J, Logan RFA, Hill PG, Khaw K-T. The iceberg of celiac disease: what is below the waterline? Clin Gastroenterol Hepatol. 2007;5:59–62.PubMed
9.
Choung RS, Larson SA, Khaleghi S, et al. Prevalence and morbidity of undiagnosed celiac disease from a community-based study. Gastroenterology. 2017;152:830–839.PubMed
10.
11.
Silano M, Volta U, Mecchia A, et al. Delayed diagnosis of coeliac disease increases cancer risk. BMC Gastroenterol. 2007;7:8.PubMedPubMedCentral
12.
Catassi C, Kryszak D, Louis-Jacques O, et al. Detection of celiac disease in primary care: a multicenter case-finding study in North America. Am J Gastroenterol. 2007;102:1454–1460.PubMed
13.
Husby S, Koletzko S, Korponay-Szabó I, et al. Hepatology and nutrition guidelines for diagnosing coeliac disease 2020. J Pediatr Gastroenterol Nutr. 2020;70:141–156.PubMed
14.
Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol. 2013;108:656–676.PubMedPubMedCentral
15.
16.
Green PHR, Stavropoulos SN, Panagi SG, et al. Characteristics of adult celiac disease in the USA: results of a national survey. Am J Gastroenterol. 2001;96:126–131.PubMed
17.
Lo W, Sano K, Lebwohl B, Diamond B, Green PHR. Changing presentation of adult celiac disease. Dig Dis Sci. 2003;48:395–398.PubMed
18.
Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for celiac disease: US preventive services task force recommendation statement. JAMA J Am Med Assoc. 2017;317:1252–1257.
19.
Hill ID, Dirks MH, Liptak GS, et al. Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2005;40:1–19.PubMed
20.
21.
Tovoli F, Negrini G, Sansone V, Faggiano C, Catenaro T, Bolondi L, et al. Celiac disease diagnosed through screening programs in at-risk adults is not associated with worse adherence to the gluten-free diet and might protect from osteopenia/osteoporosis. 2018. www.​mdpi.​com/​journal/​nutrients.
22.
Lebwohl B, Rubio-Tapia A, Guandalini S, Newland C, Assiri A. Diagnosis of celiac disease. Gastrointest Endosc Clin N Am. 2012;22(4):661.PubMedPubMedCentral
23.
Rostom A, Dubé C, Cranney A, et al. The diagnostic accuracy of serologic tests for celiac disease: a systematic review. Gastroenterology. 2005;128:S38–S46.PubMed
24.
Dieterich W, Ehnis T, Bauer M, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med. 1997;3:797–801.PubMed
25.
Troncone R, Maurano F, Rossi M, et al. IgA antibodies to tissue transglutaminase: an effective diagnostic test for celiac disease. J Pediatr. 1999;134:166–171.PubMed
26.
Dieterich W, Laag E, Schopper H, et al. Autoantibodies to tissue transglutaminase as predictors of celiac disease. Gastroenterology. 1998;115:1317–1321.PubMed
27.
Grodzinsky E, Hed J, Skogh T. IgA antiendomysium antibodies have a high positive predictive value for celiac disease in asymptomatic patients. Allergy. 1994;49:593–597.PubMed
28.
Latiff AHA, Kerr MA. The clinical significance of immunoglobulin A deficiency. Ann Clin Biochem. 2007;44:131–139.PubMed
29.
McGowan KE, Lyon ME, Butzner JD. Celiac disease and IgA deficiency: complications of serological testing approaches encountered in the clinic. Clin Chem. 2008;54:1203–1209.PubMed
30.
Lenhardt A, Plebani A, Marchetti F, et al. Role of human-tissue transglutaminase IgG and anti-gliadin IgG antibodies in the diagnosis of coeliac disease in patients with selective immunoglobulin A deficiency. Dig Liver Dis. 2004;36:730–734.PubMed
31.
Villalta D, Tonutti E, Prause C, et al. IgG antibodies against deamidated gliadin peptides for diagnosis of celiac disease in patients with IgA deficiency. Clin Chem. 2010;56:464–468.PubMed
32.
Leffler D, Schuppan D, Pallav K, et al. Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Gut. 2013;62:996–1004.PubMed
33.
Brown NK, Guandalini S, Semrad C, Kupfer SS. A clinician’s guide to celiac disease HLA genetics. Am J Gastroenterol. 2019;114:1587–1592.PubMed
34.
Almeida LM, Gandolfi L, Pratesi R, et al. Presence of DQ2.2 associated with DQ2.5 increases the risk for celiac disease. Autoimmune Dis. 2016;2016:5409653.PubMedPubMedCentral
35.
Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med. 2003;163:286–292.PubMed
36.
Rubio-Tapia A, Van Dyke CT, Lahr BD, et al. Predictors of family risk for celiac disease: a population-based study. Clin Gastroenterol Hepatol. 2008;6:983–987.PubMedPubMedCentral
37.
38.
Emilsson L, Wijmenga C, Murray JA, Ludvigsson JF. Autoimmune disease in first-degree relatives and spouses of individuals with celiac disease. Clin Gastroenterol Hepatol. 2015;13(1271–1277):e2.PubMed
39.
Wessels MMS, de Rooij N, Roovers L, Verhage J, de Vries W, Mearin ML. Towards an individual screening strategy for first-degree relatives of celiac patients. Eur J Pediatr. 2018;177:1585–1592.PubMed
40.
Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ, Davis B. Chapter 1: epidemiology of type 1 diabetes. Endocrinol Metab Clin. 2010;39:481–497.
41.
42.
Craig ME, Prinz N, Boyle CT, et al. Prevalence of celiac disease in 52,721 youth with type 1 diabetes: international comparison across three continents. Diabetes Care. 2017;40:1034–1040.PubMedPubMedCentral
43.
Smigoc Schweiger D, Mendez A, Kunilo Jamnik S, et al. High-risk genotypes HLA-DR3-DQ2/DR3-DQ2 and DR3-DQ2/DR4-DQ8 in co-occurrence of type 1 diabetes and celiac disease. Autoimmunity. 2016;49:240–247.PubMed
44.
45.
Lunt H, Florkowski CM, Cundy T, et al. A population-based study of bone mineral density in women with longstanding Type 1 (insulin dependent) diabetes. Diabetes Res Clin Pract. 1998;40:31–38.PubMed
46.
Neu A, Ehehalt S, Willasch A, Kehrer M, Hub R, Ranke MB. Rising incidence of type 1 diabetes in Germany: 12-year trend analysis in children 0–14 years of age. Diabetes Care. 2001;24(4):785–786.PubMed
47.
Diniz-Santos DR, Brandão F, Adan L, Moreira A, Vicente EJ, Silva LR. Bone mineralization in young patients with type 1 diabetes mellitus and screening-identified evidence of celiac disease. Dig Dis Sci. 2008;53:1240–1245.PubMed
48.
Leeds JS, Hopper AD, Hadjivassiliou M, Tesfaye S, Sanders DS. High prevalence of microvascular complications in adults with type 1 diabetes and newly diagnosed celiac disease. Diabetes Care. 2011;34:2158–2163.PubMedPubMedCentral
49.
Tsouka A, Mahmud FH, Marcon MA. Celiac disease alone and associated with type 1 diabetes mellitus. J Pediatr Gastroenterol Nutr. 2015;61:297–302.PubMed
50.
51.
Hanley P, Lord K, Bauer AJ. Thyroid disorders in children and adolescents: a review. JAMA Pediatr. 2016;170:1008–1019.PubMed
52.
Kahaly GJ, Frommer L, Schuppan D. Celiac disease and endocrine autoimmunity—the genetic link. Autoimmun Rev. 2018;17:1169–1175.PubMed
53.
54.
Meloni GF, Tomasi PA, Bertoncelli A, Fanciulli G, Delitala G, Meloni T. Prevalence of silent celiac disease in patients with autoimmune thyroiditis from Northern Sardinia. J Endocrinol Invest. 2001;24:298–302.PubMed
55.
Larizza D, Calcaterra V, De Giacomo C, et al. Celiac disease in children with autoimmune thyroid disease. J Pediatr. 2001;139:738–740.PubMed
56.
Canova C, Pitter G, Ludvigsson JF, et al. Celiac disease and risk of autoimmune disorders: a population-based matched birth cohort study. J Pediatr. 2016;174:146–152.PubMed
57.
Reilly NR, Verma R. Time to screen children with celiac disease for thyroid disease? J Pediatr. 2016;174:7–9.PubMed
58.
59.
Virili C, Bassotti G, Santaguida MG, et al. Atypical celiac disease as cause of increased need for thyroxine: a systematic study. J Clin Endocrinol Metab. 2012;97:E419–E422.PubMed
60.
Kassebaum NJ, Jasrasaria R, Naghavi M, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123:615–624.PubMedPubMedCentral
61.
Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372:1832–1843.PubMed
62.
Yanatori I, Kishi F. DMT1 and iron transport. Free Radic Biol Med. 2019;133:55–63.PubMed
63.
Hershko C, Camaschella C. How I treat unexplained refractory iron deficiency anemia. Blood. 2014;123:326–333.PubMed
64.
Mahadev S, Laszkowska M, Sundström J, et al. Prevalence of celiac disease in patients with iron deficiency anemia—a systematic review with meta-analysis. Gastroenterology. 2018;155:374–382.PubMedPubMedCentral
65.
66.
Repo M, Lindfors K, Mäki M, et al. Anemia and iron deficiency in children with potential celiac disease. J Pediatr Gastroenterol Nutr. 2017;64:56–62.PubMed
67.
Hershko C, Hoffbrand AV, Keret D, et al. Role of autoimmune gastritis, Helicobacter pylori and celiac disease in refractory or unexplained iron deficiency anemia. Haematologica. 2005;90:585–595.PubMed
68.
Ransford RAJ, Hayes M, Palmer M, Hall MJ. A controlled, prospective screening study of celiac disease presenting as iron deficiency anemia. J Clin Gastroenterol. 2002;35:228–233.PubMed
69.
Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150:1393–1407.
70.
Lovell RM, Ford AC. Global prevalence of and risk factors for irritable Bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10:712–721.PubMed
71.
Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable Bowel syndrome. Gastroenterology. 2014;146:67–75.PubMed
72.
Shahbazkhani B, Sadeghi A, Malekzadeh R, et al. Non-celiac gluten sensitivity has narrowed the spectrum of irritable Bowel syndrome: a double-blind randomized placebo-controlled trial. Nutrients. 2015;7:4542–4554.PubMedPubMedCentral
73.
Skodje GI, Sarna VK, Minelle IH, et al. Fructan, rather than gluten, induces symptoms in patients with self-reported non-celiac gluten sensitivity. Gastroenterology. 2018;154:529–539.PubMed
74.
Ford AC, Chey WD, Talley NJ, Malhotra A, Spiegel BMR, Moayyedi P. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome systematic review and meta-analysis. Arch Intern Med. 2009;169:651–658.PubMed
75.
Irvine AJ, Chey WD, Ford AC. Screening for celiac disease in irritable Bowel syndrome: an updated systematic review and meta-analysis. Am J Gastroenterol. 2017;112:65–76.PubMed
76.
77.
Spiegel BMR, Derosa VP, Gralnek IM, Wang V, Dulai GS. Testing for Celiac Sprue in Irritable Bowel Syndrome With Predominant Diarrhea: A Cost-Effectiveness Analysis. 2004;
78.
79.
Mohseninejad L, Feenstra T, Van Der Horst HE, Woutersen-Koch L, et al. Targeted screening for coeliac disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information. Eur J Health Econ. 2013;14:947–957.PubMed
80.
81.
Zone JJ. Skin manifestations of celiac disease. Gastroenterology. 2005;128:S87–S91.PubMed
82.
Kelly CP. Celiac Disease and Refractory Celiac Disease. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. United Kingdom: Elsevier Health Science; 2010. p. 1797–1820.
83.
Bolotin D, Petronic-Rosic V. Dermatitis herpetiformis: part I. Epidemiology, pathogenesis, and clinical presentation. J Am Acad Dermatol. 2011;64:1017–1024.PubMed
84.
85.
Zone JJ, Meyer LJ, Petersen MJ. Deposition of granular IgA relative to clinical lesions in dermatitis herpetiformis. Arch Dermatol. 1996;132:912–918.PubMed
86.
Marks J. Small-bowel changes in dermatitis herpetiformis. Lancet. 1966;288:1280–1282.
87.
Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol. 2001;45:420–434.PubMed
88.
Garioch JJ, Lewis HM, Sargent SA, Leonard JN, Fry L. 25 years’ experience of a gluten-free diet in the treatment of dermatitis herpetiformis. Br J Dermatol. 1994;131:541–545.PubMed
89.
Rodrigues F, Bachmeyer C. Coeliac disease and dermatitis herpetiformis. The Lancet. 2018;392:916.
90.
91.
Roizen NJ, Patterson D. Down’s syndrome. Lancet. 2003;361(9365):1281–1289.PubMed
92.
Mårild K, Stephansson O, Grahnquist L, Cnattingius S, Söderman G, Ludvigsson JF. Down syndrome is associated with elevated risk of celiac disease: a nationwide case–control study. J Pediatr. 2013;163:237–242.PubMed
93.
94.
Bull MJ, Saal HM, Braddock SR, et al. Clinical report—health supervision for children with Down syndrome. Pediatrics. 2011;128:393–406.PubMed
95.
96.
Bondy CA. Clinical practice guideline: care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab. 2007;92:10–25.PubMed
97.
Goldacre MJ, Seminog OO. Turner syndrome and autoimmune diseases: record-linkage study. Arch Dis Child. 2014;99:71–73.PubMed
98.
Mårild K, Størdal K, Hagman A, Ludvigsson JF. Turner syndrome and celiac disease: a case–control study. Pediatrics. 2016;137:20152232.
99.
Rajani S, Huynh HQ, Turner J. The changing frequency of celiac disease diagnosed at the Stollery Children’s Hospital. Can J Gastroenterol. 2010;24. www.​cdc.​gov/​epi.
100.
Metadata
Title
Celiac Disease Screening for High-Risk Groups: Are We Doing It Right?
Authors
Dennis Kumral
Sana Syed
Publication date
01-08-2020

Other articles of this Issue 8/2020

Digestive Diseases and Sciences 8/2020 Go to the issue

Editorial

Improving Detection Rates of Giardia Using Duodenal Biopsy PCR: Is the Juice Worth the Squeeze?

FELLOWS AND YOUNG GIS SECTION

How to Become a Competitive Applicant for Gastroenterology Fellowship: Tips and Tricks for Success Part II

Original Article

Ninety-Six Hour Wireless Esophageal pH Study in Patients with GERD Shows that Restrictive Diet Reduces Esophageal Acid Exposure

FELLOWS AND YOUNG GIS SECTION

The New Virtual Reality: How COVID-19 Will Affect the Gastroenterology and Hepatology Fellowship Match

Current Clinical Controversy

PPIs and Beyond: A Framework for Managing Anticoagulation-Related Gastrointestinal Bleeding in the Era of COVID-19

Original Article

Upper Gastrointestinal Disease Influences the Occurrence of Inflammatory Bowel Disease
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits